Skip to content
CancerIndex

Publication

Blinatumomab Care Delivery for Pediatric B-Cell Acute Lymphoblastic Leukemia.

Daniel J Zheng, Katelyn Oranges, Subhash Ramakrishnan, Lingyun Ji, Melissa P Beauchemin, Sarah W Alexander, Allison Barz Leahy, Kira Bona, Emi H Caywood, Sharon M Castellino, Sumit Gupta, Douglas S Hawkins, Olga Militano, Kathleen E Montgomery, Haley Newman, Rachel E Rau, Susan Rheingold, Joanna M Robles, Michael E Roth, David Teachey, Sarah Vargas, Sue Zupanec, Susan K Parsons

JAMA network openSep 1, 2026PMID 42709436doi:10.1001/jamanetworkopen.2026.32786 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 10, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260910-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

IMPORTANCE: Blinatumomab, a novel immunotherapy administered as a 28-day continuous infusion, has fundamentally shifted the treatment paradigm for pediatric B-cell acute lymphoblastic leukemia (B-ALL) and is now considered a component of standard therapy for the most common childhood cancer.…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.